These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36142323)

  • 1. Hypoxia-Inducible Factors and Diabetic Kidney Disease-How Deep Can We Go?
    Stanigut AM; Pana C; Enciu M; Deacu M; Cimpineanu B; Tuta LA
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
    Packer M
    Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Hasegawa S; Tanaka T; Saito T; Fukui K; Wakashima T; Susaki EA; Ueda HR; Nangaku M
    Kidney Int; 2020 May; 97(5):934-950. PubMed ID: 32171449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].
    Nangaku M
    Rinsho Ketsueki; 2021; 62(8):938-943. PubMed ID: 34497234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding roles of the hypoxia-response network in chronic kidney disease.
    Tanaka T
    Clin Exp Nephrol; 2016 Dec; 20(6):835-844. PubMed ID: 26857707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Hasegawa S; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model.
    Ohtomo S; Nangaku M; Izuhara Y; Takizawa S; Strihou Cv; Miyata T
    Nephrol Dial Transplant; 2008 Apr; 23(4):1166-72. PubMed ID: 17967803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia and hypoxia-inducible factors in diabetes and its complications.
    Catrina SB; Zheng X
    Diabetologia; 2021 Apr; 64(4):709-716. PubMed ID: 33496820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrogen sulfide upregulates hypoxia inducible factors and erythropoietin production in chronic kidney disease induced by 5/6 nephrectomized rats.
    Hajiaqaei M; Ranjbaran M; Kadkhodaee M; Shafie A; Abdi A; Lorian K; Kianian F; Seifi B
    Mol Biol Rep; 2024 Aug; 51(1):916. PubMed ID: 39158746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor activation in diabetic kidney disease.
    Persson P; Palm F
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):345-350. PubMed ID: 28538016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M; Tanaka T; Nangaku M
    Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D; Macdougall IC
    Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic Targeting of Hypoxia-Inducible Factors.
    Semenza GL
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():379-403. PubMed ID: 30625281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.